2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 198

CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus
Abstract Number: 1174

Class 3 Semaphorins Modulate the Invasive Capacity of Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 421

Clinical Analysis and Outcome of Interstitial Lung Disease with Juvenile Dermatomyositis
Abstract Number: 1538

Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Abstract Number: 2183

Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Abstract Number: 2452

Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab
Abstract Number: 221

Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Abstract Number: 713

Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Abstract Number: 693

Clinical and Imaging Features of Reactive Arthritis in Guatemala City
Abstract Number: 766

Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica
Abstract Number: 2729

Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis
Abstract Number: 389

Clinical and Serological Differences Between Juvenile-Onset and Adult-Onset Systemic LUPUS Erythematosus Patients from a National Registry of Patients
Abstract Number: 398

Clinical and Serological Profile of Children with Positive SSA-Ro/SSB-La Antibodies
Abstract Number: 1382

Clinical and Serum IgG4 Characteristics of a Unique British Columbian IgG4-Related Disease Cohort
Abstract Number: 468

Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].